Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Target Validation and Discovery in Idiopathic Bronchiectasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03750734
Recruitment Status : Not yet recruiting
First Posted : November 22, 2018
Last Update Posted : March 28, 2019
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Papworth Hospital NHS Foundation Trust

Brief Summary:

Bronchiectasis is a long-term lung condition where the airways become abnormally enlarged, leading to a build-up of mucus and inflammation that makes the lungs more susceptible to recurrent infection. Patients with bronchiectasis have subtle abnormalities in the way their airway cells respond to infection that are, in part, responsible for the development of their condition. At present there are no licensed treatments for bronchiectasis.

This study will aim to characterise in depth some of these abnormalities with a view to future studies that will try to develop treatments that can directly target those abnormalities at a molecular level.

Patients known to have bronchiectasis who have provided written informed consent will be enrolled alongside healthy volunteers and patients with chronic obstructive pulmonary disease and cystic fibrosis, for comparison. Participants will give a blood sample and have a bronchoscopy. This is a thin telescopic tube, passed through the nose or mouth, under sedation, into the airways that will allow a sample of bronchial epithelial cells to be taken.

The main objective of the study is to achieve a greater understanding of some of the key biological processes/pathways and disease marker genes that play a role in the development of bronchiectasis. This is important because, at present, little is known about the underlying disease mechanisms and there are no licensed treatments for bronchiectasis.

The investigator's hope this in-depth characterisation of specific bronchial epithelial cell abnormalities in bronchiectasis will shed light on novel targets for future drug discovery.


Condition or disease Intervention/treatment
Bronchiectasis Idiopathic Bronchiectasis Diagnostic Test: Bronchoscopy Diagnostic Test: Blood test

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Target Validation and Discovery in Idiopathic Bronchiectasis
Estimated Study Start Date : May 2019
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2022

Group/Cohort Intervention/treatment
Idiopathic bronchiectasis
Idiopathic bronchiectasis participants
Diagnostic Test: Bronchoscopy
Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.

Diagnostic Test: Blood test
Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.

COPD
Chronic obstructive pulmonary disease participants
Diagnostic Test: Bronchoscopy
Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.

Diagnostic Test: Blood test
Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.

Cystic fibrosis
Cystic fibrosis participants
Diagnostic Test: Bronchoscopy
Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.

Diagnostic Test: Blood test
Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.

Healthy volunteers
Healthy volunteers
Diagnostic Test: Bronchoscopy
Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.

Diagnostic Test: Blood test
Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.




Primary Outcome Measures :
  1. Identification and comparison of molecular pathways, including through gene expression analysis of airway tissues. [ Time Frame: 2 years ]
    Identification and comparison of molecular pathways, including through gene expression analysis of airway tissues.


Secondary Outcome Measures :
  1. Generation of air liquid interface cultures from primary bronchial epithelial cells/IPSC derived bronchial epithelial cells [ Time Frame: 2 years ]
    Generation of air liquid interface cultures from primary bronchial epithelial cells/IPSC derived bronchial epithelial cells

  2. Functional characterisation of airway epithelium [ Time Frame: 2 years ]
    Functional characterisation of airway epithelium


Biospecimen Retention:   Samples With DNA
Whole blood, bronchial biopsy, bronchial brushings, bronchoalveolar lavage


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Secondary care respiratory clinics
Criteria

Inclusion Criteria:

Bronchiectasis participants

  1. Confirmed HRCT diagnosis of bronchiectasis in more than 1 lobe
  2. Bronchiectasis not attributable to another cause, e.g. cystic fibrosis/ABPA/PCD
  3. Absence of significant emphysema, COPD or asthma
  4. Have provided written informed consent that they are willing to participate in the study prior to sample collection

COPD participants (disease controls)

  1. Confirmed diagnosis of COPD according to GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria (FEV1/FVC ratio < 0.70)
  2. Absence of significant bronchiectasis on HRCT
  3. Have provided written informed consent that they are willing to participate in the study prior to sample collection

Cystic fibrosis participants (disease controls)

  1. Have a confirmed diagnosis of cystic fibrosis
  2. Have provided written informed consent that they are willing to participate in the study prior to sample collection

Healthy controls

  1. No history or diagnosis of clinically significant lung disease
  2. Be a non-smoker for > 1 year at screening and have < 5 pack year history of smoking
  3. Have provided written informed consent that they are willing to participate in the study prior to sample collection

Exclusion Criteria:

  1. Any clinically significant acute illness, including recent exacerbation of lung disease requiring treatment with oral or intravenous antibiotics, in 6 weeks prior to screening
  2. Any contraindication to safe bronchoscopy as judged by CI or clinical team (FEV1 < 30% predicted, oxygen saturations < 92% on room air etc.)
  3. Any clinically significant bleeding disorder or use of anticoagulant/antiplatelet therapy that could place participants at risk of bleeding
  4. Any contraindication to sedation or local anaesthetic medications used for bronchoscopy
  5. Current smoking within 6 months prior to screening (defined as someone who has smoked at least one cigarette per day (or pipe, cigar, or cannabis) for ≥ 30 days within 6 months prior to screening)
  6. Acute MI, acute stroke or major surgery within 6 months prior to screening
  7. History of uncontrolled ischaemic heart disease that place participants at risk during bronchoscopy
  8. History of ventilatory failure or hypercapnia that may complicate bronchoscopy
  9. Any known active tuberculous or non-tuberculous mycobacterial infection
  10. Any use of oral corticosteroids within 4 weeks of screening
  11. Any systemic immunomodulatory or immunosuppressive therapy within 3 months of screening
  12. Known current malignancy or current evaluation for a potential malignancy
  13. Any other clinically significant medical disease that is uncontrolled despite treatment, that is likely, in the opinion of the investigators, to impact the patient's ability to safely participate in the study

Layout table for additonal information
Responsible Party: Papworth Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT03750734     History of Changes
Other Study ID Numbers: P02437
First Posted: November 22, 2018    Key Record Dates
Last Update Posted: March 28, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchiectasis
Bronchial Diseases
Respiratory Tract Diseases